Guidance

National protocol for Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant])

This protocol is for the administration of Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]) to individuals in accordance with the national COVID-19 vaccination programme.

From:
UK Health Security Agency
Published
10 May 2022

This publication was withdrawn on

This document was withdrawn on 2 September 2022 as all stock has expired. See COVID-19 vaccination programme for current national protocols.

Applies to England

Documents

[Withdrawn] National protocol for Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant])

Ref: UKHSA gateway number GOV-12178

MS Word Document, 237 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This protocol is for the administration of Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]) by appropriately trained persons.

National protocol for Vaxzevria COVID-19 Vaccine (ChAdOx1-S [recombinant]) v01.00 is valid from 10 May 2022 to 1 April 2023.

Updates to this page

Published 10 May 2022

Sign up for emails or print this page